SG11202103560YA - Inhibitors of human immunodeficiency virus replication - Google Patents
Inhibitors of human immunodeficiency virus replicationInfo
- Publication number
- SG11202103560YA SG11202103560YA SG11202103560YA SG11202103560YA SG11202103560YA SG 11202103560Y A SG11202103560Y A SG 11202103560YA SG 11202103560Y A SG11202103560Y A SG 11202103560YA SG 11202103560Y A SG11202103560Y A SG 11202103560YA SG 11202103560Y A SG11202103560Y A SG 11202103560YA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- immunodeficiency virus
- human immunodeficiency
- virus replication
- replication
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749818P | 2018-10-24 | 2018-10-24 | |
| PCT/IB2019/059020 WO2020084492A1 (en) | 2018-10-24 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103560YA true SG11202103560YA (en) | 2021-05-28 |
Family
ID=68344933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103560YA SG11202103560YA (en) | 2018-10-24 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11541055B2 (ja) |
| EP (1) | EP3870577A1 (ja) |
| JP (1) | JP7398448B2 (ja) |
| KR (1) | KR20210084508A (ja) |
| CN (1) | CN113195475A (ja) |
| AR (1) | AR116798A1 (ja) |
| AU (1) | AU2019364739B2 (ja) |
| BR (1) | BR112021007362A2 (ja) |
| CA (1) | CA3117289A1 (ja) |
| CL (1) | CL2021001025A1 (ja) |
| CO (1) | CO2021004679A2 (ja) |
| CR (1) | CR20210207A (ja) |
| DO (1) | DOP2021000062A (ja) |
| EA (1) | EA202190854A1 (ja) |
| IL (1) | IL282240A (ja) |
| MA (1) | MA53973A (ja) |
| MX (1) | MX2021004593A (ja) |
| PE (1) | PE20211781A1 (ja) |
| PH (1) | PH12021550813A1 (ja) |
| SG (1) | SG11202103560YA (ja) |
| TW (1) | TWI824041B (ja) |
| WO (1) | WO2020084492A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| TWI824041B (zh) * | 2018-10-24 | 2023-12-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫缺乏病毒複製之抑制劑 |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| TW202133858A (zh) | 2019-11-28 | 2021-09-16 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥 |
| JP2023505543A (ja) | 2019-12-09 | 2023-02-09 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
| CA3234219A1 (en) | 2021-10-13 | 2023-04-20 | Gautam Dalwadi | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1670768T3 (pl) | 2003-10-08 | 2010-01-29 | Lilly Co Eli | Związki i sposoby leczenia dyslipidemii |
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| JP2012201642A (ja) * | 2011-03-25 | 2012-10-22 | Tsutomu Takeuchi | １−フェニルピロリジン−２，５−ジオン誘導体を有効成分とするｂａｆｆの結合阻害剤 |
| WO2013006738A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9012441B2 (en) | 2013-01-09 | 2015-04-21 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP5941598B2 (ja) | 2013-01-09 | 2016-06-29 | ギリアード サイエンシーズ， インコーポレイテッド | ５員ヘテロアリールおよびそれらの抗ウイルス剤としての使用 |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| AU2015306779B2 (en) * | 2014-08-27 | 2017-11-02 | VIIV Healthcare UK (NO.5) Ltd | Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| MA42795B1 (fr) | 2016-08-19 | 2019-08-30 | Gilead Sciences Inc | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih |
| TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| CN111836805B (zh) | 2018-02-15 | 2023-07-14 | 吉利德科学公司 | 吡啶衍生物及其用于治疗hiv感染的用途 |
| KR20230145536A (ko) | 2018-02-16 | 2023-10-17 | 길리애드 사이언시즈, 인코포레이티드 | 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체 |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| BR112021001617A2 (pt) | 2018-08-09 | 2021-04-27 | VIIV Healthcare UK (No.5) Limited | inibidores de replicação do vírus da imunodeficiência humana |
| US20220089598A1 (en) | 2018-09-14 | 2022-03-24 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| EP3853228A1 (en) | 2018-09-20 | 2021-07-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| FR3086760A1 (fr) | 2018-10-02 | 2020-04-03 | Institut Mines Telecom | Procede d'evaluation de la resistance mecanique d'un echantillon de tissu biologique |
| JP2022505637A (ja) | 2018-10-24 | 2022-01-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| TWI824041B (zh) * | 2018-10-24 | 2023-12-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫缺乏病毒複製之抑制劑 |
| JP7500555B2 (ja) | 2018-10-25 | 2024-06-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| JP2022505989A (ja) | 2018-10-29 | 2022-01-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | キナゾリニル－インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用 |
| WO2020095176A1 (en) | 2018-11-05 | 2020-05-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US20210395248A1 (en) | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| US11429555B2 (en) | 2019-02-26 | 2022-08-30 | Apple Inc. | Coprocessors with bypass optimization, variable grid architecture, and fused vector operations |
| CN112074195A (zh) | 2019-04-11 | 2020-12-11 | 高丽营养有限公司 | 苹果醋营养补充剂 |
| WO2020222108A1 (en) | 2019-04-30 | 2020-11-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN114245795A (zh) | 2019-06-19 | 2022-03-25 | Viiv保健英国第五有限公司 | 作为人类免疫缺陷病毒复制抑制剂的吡啶并[2,3-d]嘧啶衍生物 |
| WO2021064571A1 (en) | 2019-10-01 | 2021-04-08 | VIIV Healthcare UK (No.5) Limited | N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| EP4038064B1 (en) | 2019-10-01 | 2024-02-21 | VIIV Healthcare UK (No.5) Limited | N-substututed-6-oxo-1,6-dihydropyrimidine-2-yl derivatives as inhibitors of the human immunodeficiency virus replication |
| TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| EP4114527A1 (en) | 2020-03-06 | 2023-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
-
2019
- 2019-10-22 TW TW108138086A patent/TWI824041B/zh active
- 2019-10-22 CN CN201980085915.8A patent/CN113195475A/zh active Pending
- 2019-10-22 AU AU2019364739A patent/AU2019364739B2/en active Active
- 2019-10-22 MA MA053973A patent/MA53973A/fr unknown
- 2019-10-22 BR BR112021007362-0A patent/BR112021007362A2/pt unknown
- 2019-10-22 AR ARP190103016A patent/AR116798A1/es unknown
- 2019-10-22 MX MX2021004593A patent/MX2021004593A/es unknown
- 2019-10-22 CR CR20210207A patent/CR20210207A/es unknown
- 2019-10-22 CA CA3117289A patent/CA3117289A1/en active Pending
- 2019-10-22 JP JP2021522518A patent/JP7398448B2/ja active Active
- 2019-10-22 PE PE2021000571A patent/PE20211781A1/es unknown
- 2019-10-22 EP EP19794683.3A patent/EP3870577A1/en active Pending
- 2019-10-22 KR KR1020217015003A patent/KR20210084508A/ko active Search and Examination
- 2019-10-22 WO PCT/IB2019/059020 patent/WO2020084492A1/en unknown
- 2019-10-22 US US16/762,209 patent/US11541055B2/en active Active
- 2019-10-22 SG SG11202103560YA patent/SG11202103560YA/en unknown
- 2019-10-22 EA EA202190854A patent/EA202190854A1/ru unknown
-
2021
- 2021-04-08 PH PH12021550813A patent/PH12021550813A1/en unknown
- 2021-04-09 DO DO2021000062A patent/DOP2021000062A/es unknown
- 2021-04-11 IL IL282240A patent/IL282240A/en unknown
- 2021-04-14 CO CONC2021/0004679A patent/CO2021004679A2/es unknown
- 2021-04-22 CL CL2021001025A patent/CL2021001025A1/es unknown
-
2022
- 2022-09-30 US US17/957,569 patent/US20230109662A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021004679A2 (es) | 2021-04-30 |
| PE20211781A1 (es) | 2021-09-08 |
| AR116798A1 (es) | 2021-06-16 |
| PH12021550813A1 (en) | 2021-10-04 |
| TWI824041B (zh) | 2023-12-01 |
| JP2022505841A (ja) | 2022-01-14 |
| US20230109662A1 (en) | 2023-04-06 |
| BR112021007362A2 (pt) | 2021-07-20 |
| JP7398448B2 (ja) | 2023-12-14 |
| AU2019364739A1 (en) | 2021-05-20 |
| CR20210207A (es) | 2021-09-02 |
| EA202190854A1 (ru) | 2021-08-17 |
| TW202031261A (zh) | 2020-09-01 |
| MX2021004593A (es) | 2021-06-15 |
| US20200360384A1 (en) | 2020-11-19 |
| AU2019364739B2 (en) | 2022-05-26 |
| CA3117289A1 (en) | 2020-04-30 |
| CL2021001025A1 (es) | 2021-11-05 |
| KR20210084508A (ko) | 2021-07-07 |
| MA53973A (fr) | 2022-02-09 |
| IL282240A (en) | 2021-05-31 |
| CN113195475A (zh) | 2021-07-30 |
| DOP2021000062A (es) | 2021-09-15 |
| US11541055B2 (en) | 2023-01-03 |
| EP3870577A1 (en) | 2021-09-01 |
| WO2020084492A1 (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3619205T (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| PT3286166T (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| IL282240A (en) | Inhibitors of human immunodeficiency virus replication | |
| PT3917930T (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| IL247309A0 (en) | Preparations for inhibiting virus replication and methods for their preparation and use | |
| HK1256903A1 (zh) | 治療人免疫缺陷病毒的治療組合物 | |
| EP3774775C0 (en) | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNO DEFICIENCY VIRUS REPLICATION | |
| IL245213A0 (en) | Inhibitors of human immunodeficiency virus replication | |
| PT3478662T (pt) | Derivados de azadecalina como inibidores da replicação do vírus da imunodeficiência humana | |
| EP3873607C0 (en) | CHINAZOLINYLINDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| EP3498726A4 (en) | DNA-BINDING PROTEIN WITH PPR MOTIF AND USE OF THE DNA-BINDING PROTEIN | |
| HK1252416A1 (zh) | 流感病毒複製抑制劑及其用途 | |
| IL257247A (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| PT3870575T (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| IL282018A (en) | Combinations of inhibitors of influenza virus replication | |
| IL269900B (en) | Antecedents of pyrrolopyriminine are useful as replication inhibitors for the influenza virus | |
| PT3107913T (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| EP3091990A4 (en) | Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome | |
| ZA201800720B (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| EP3426353A4 (en) | USE OF MODIFIED HIV-1 TO GENERATE FULLY HUMAN ANTIBODIES | |
| IL257157A (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| IL256450A (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| EP4038064C0 (en) | N-SUBSTITUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | |
| PT3105236T (pt) | Macrociclos de benzotiazole como inibidores da replicação do vírus da imunodeficiência humana | |
| EP4041729C0 (en) | INHIBITORS OF THE NEW FORMATION OF HUMAN IMMUNODEFECT VIRUSES |